Skip to main content

and
  1. No Access

    Article

    Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

    Claudin18.2 (CLDN18.2) is highly expressed with the development of various malignant tumors, especially gastrointestinal cancers, and is emerging as a new target for cancer treatment. Satricabtagene autoleucel...

    Changsong Qi, Chang Liu, Jifang Gong, Dan Liu, **cheng Wang in Nature Medicine (2024)

  2. Article

    Open Access

    Influential upregulation of KCNE4: Propelling cancer associated fibroblasts-driven colorectal cancer progression

    Colorectal cancer (CRC) is a malignancy of remarkable heterogeneity and heightened morbidity. Cancer associated fibroblasts (CAFs) are abundant in CRC tissues and are essential for CRC growth. Here, we aimed t...

    Zizhen Zhang, Shengde Liu, Zhenghang Wang, Shuo Wang in Cancer Cell International (2024)

  3. Article

    Open Access

    Advances in KRAS mutation inhibition in metastatic colorectal cancer

    KRAS is the most frequently mutated oncogene in human malignancies, observed in approximately two in five colorectal cancers (CRC). KRAS mutations were historically considered “undruggable” ten years ago and asso...

    Chunhua Wu, Wenfei Li, Mifen Chen, Qi Zhang, Ting Xu in Holistic Integrative Oncology (2023)

  4. Article

    Open Access

    Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results

    Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CAR T cells showed pro...

    Changsong Qi, Jifang Gong, Jian Li, Dan Liu, Yanru Qin, Sai Ge in Nature Medicine (2022)

  5. Article

    Open Access

    Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma

    A significant subset of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) gastric adenocarcinomas (GAC) are resistant to immune checkpoint inhibitors (ICIs), yet the underlying mechanism...

    Zhenghang Wang, **nyu Wang, Yu Xu, Jian Li, **aotian Zhang, Zhi Peng in BMC Medicine (2022)

  6. Article

    Open Access

    PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients

    Immunotherapy has emerged as an effective therapeutic strategy for various cancers, including colorectal cancer (CRC), but only a subset of MSI-H patients can benefit from such therapy. Patched1 (PTCH1) is a freq...

    Yanni Wang, Huan Chen, ** Jiao, Lihong Wu, Ying Yang in Cancer Immunology, Immunotherapy (2022)

  7. Article

    Open Access

    Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer

    The human leukocyte antigen class I (HLA-I) genotype has been linked with differential immune responses to infectious disease and cancer. However, the clinical relevance of germline HLA-mediated immunity in ga...

    Zhihao Lu, Huan Chen, ** Jiao, Yujiao Wang, Lijia Wu, Huaibo Sun in Genome Medicine (2021)

  8. No Access

    Article

    Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy

    Circulating tumor DNA (ctDNA) is considered an ideal sample type for genoty** patients with advanced unresectable cancer to inform treatment decision. It may better capture tumor heterogeneity, especially in...

    Meng Zhang, Changsong Qi, Zhenghang Wang, Hui Chen in Journal of Molecular Medicine (2021)

  9. Article

    Open Access

    Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors

    RC48 contains the novel humanized anti-HER2 antibody hertuzumab conjugated to MMAE via a cleavable linker. A phase I study was initiated to evaluate the toxicity, MTD, PK, and antitumor activity of RC48 in pat...

    Yingying Xu, Yakun Wang, Jifang Gong, **aotian Zhang, Zhi Peng in Gastric Cancer (2021)

  10. Article

    Open Access

    A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer

    The association between genetic variations and immunotherapy benefit has been widely recognized, while such evidence in gastrointestinal cancer remains limited. We analyzed the genomic profile of 227 immunothe...

    ** Jiao, **n Wei, Shuang Li, Chang Liu, Huan Chen, Jifang Gong in npj Precision Oncology (2021)

  11. Article

    Open Access

    Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition)

    The lungs are the second most common site of metastasis for colorectal cancer (CRC) after the liver. Rectal cancer is associated with a higher incidence of lung metastases compared to colon cancer. In China, t...

    Jian Li, Ying Yuan, Fan Yang, Yi Wang, Xu Zhu in Journal of Hematology & Oncology (2019)

  12. No Access

    Article

    QTL map** for developmental behavior of plant height in wheat (Triticum aestivum L.)

    A recombinant inbred line (RIL) population with 305 lines derived from a cross of Hanxuan 10 × Lumai 14 was used to identify the dynamic quantitative trait loci (QTL) for plant height (PH) in wheat (Triticum aest...

    Zhenghang Wang, **anshan Wu, Qian Ren, ** Chang, Runzhi Li, Ruilian **g in Euphytica (2010)